Organ Crosstalk in Obesity and NAFLD
joint with Bioenergetics and Metabolic Disease
Organizer(s): Gary J. Schwartz, Bei B. Zhang and Christoph BuettnerDate: January 21 - 25, 2018
Location: Keystone Resort, Keystone, CO, USA
Neural and humoral communication among peripheral organs and the brain is critical in coordinating whole body energy homeostasis in health and disease. Nutrient and hormone sensing take place in multiple organs with the central nervous system as a site of integration of these diverse signals, governing this coordination. Within this multi-organ framework, the liver occupies a central role in determining systemic glucose and lipid metabolism in obesity and clinically relevant metabolic pathophysiology, particularly non-alcoholic fatty liver disease (NAFLD) and fibrosis. Identification and characterization of the modes and consequences of organ cross-talk is essential to fill existing gaps in knowledge and to promote the development of therapeutic strategies to treat obesity and metabolic disease. This conference brings together experts in the novel, multidisciplinary evaluation of organ cross-talk, using innovative combinations of molecular, genetic, physiological, pharmacological and systems neuroscience approaches to: 1) Provide a unique and timely perspective, and 2) Inspire interactions directed toward basic, clinical and translational research in integrative metabolism. Finally, the joint staging of this conference in conjunction with the conference on “Bioenergetics and Metabolic Disease” will strategically leverage presentations targeting the biology of metabolism and nutrient availability in obesity with those focused on the biology of energy utilization. Taken together, this novel combination will provide a coherent, powerful and comprehensive understanding of and appreciation for the complex.
Scholarship Deadline: September 28 2017
Discounted Abstract Deadline: September 28 2017
Abstract Deadline: October 26 2017
Discounted Registration Deadline: November 29 2017
We gratefully acknowledge additional support from these exhibitors at this conference:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Janssen R&D: Pharmaceutical Companies of Johnson & Johnson
Pfizer Research Technology Center
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 5R13DK104611-04
Funding for this conference was made possible (in part) by 5R13DK104611-04 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.